These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

633 related items for PubMed ID: 25907243

  • 1. Biological drugs in ANCA-associated vasculitis.
    Lutalo PM, D'Cruz DP.
    Int Immunopharmacol; 2015 Aug; 27(2):209-12. PubMed ID: 25907243
    [Abstract] [Full Text] [Related]

  • 2. Biologics for ANCA-associated vasculitis.
    Murgia G, Firinu D, Manconi PE, Del Giacco SR.
    Inflamm Allergy Drug Targets; 2014 Aug; 13(4):275-87. PubMed ID: 24998311
    [Abstract] [Full Text] [Related]

  • 3. Targeted immunotherapy strategies in ANCA-associated vasculitis.
    Puéchal X.
    Joint Bone Spine; 2019 May; 86(3):321-326. PubMed ID: 30201478
    [Abstract] [Full Text] [Related]

  • 4. New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis.
    Nozaki Y.
    Front Immunol; 2021 May; 12():631055. PubMed ID: 33868250
    [Abstract] [Full Text] [Related]

  • 5. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A, Lenert P.
    Drug Des Devel Ther; 2015 May; 9():333-47. PubMed ID: 25609919
    [Abstract] [Full Text] [Related]

  • 6. Novel Therapies for ANCA-associated Vasculitis.
    Monti S, Brandolino F, Milanesi A, Xoxi B, Delvino P, Montecucco C.
    Curr Rheumatol Rep; 2021 Apr 28; 23(6):38. PubMed ID: 33909172
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Vasculitis for the internist: focus on ANCA-associated vasculitis.
    Chaigne B, Guillevin L.
    Intern Emerg Med; 2017 Aug 28; 12(5):577-585. PubMed ID: 28623488
    [Abstract] [Full Text] [Related]

  • 9. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H, Lee SM, Manno RL, Seo P, Geetha D.
    Semin Arthritis Rheum; 2015 Aug 28; 45(1):67-9. PubMed ID: 25796088
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
    Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, Marie I, Khellaf M, Kahn JE, Karras A, Ziza JM, Deligny C, Tchérakian C, Guillevin L, French Vasculitis Study Group.
    Rheumatology (Oxford); 2014 Mar 28; 53(3):532-9. PubMed ID: 24282319
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.
    Cartin-Ceba R, Fervenza FC, Specks U.
    Curr Opin Rheumatol; 2012 Jan 28; 24(1):15-23. PubMed ID: 22089095
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention.
    Kallenberg CG, Stegeman CA, Abdulahad WH, Heeringa P.
    Am J Kidney Dis; 2013 Dec 28; 62(6):1176-87. PubMed ID: 23810690
    [Abstract] [Full Text] [Related]

  • 19. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
    Jones RB.
    Nephron Clin Pract; 2014 Dec 28; 128(3-4):243-9. PubMed ID: 25401382
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.